Department of Neurological Surgery, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213, USA.
Int J Radiat Oncol Biol Phys. 2010 Feb 1;76(2):520-7. doi: 10.1016/j.ijrobp.2009.01.076. Epub 2009 Sep 23.
To evaluate the outcome of repeat stereotactic radiosurgery (SRS) for acoustic neuromas, we assessed tumor control, clinical outcomes, and the risk of adverse radiation effects in patients whose tumors progressed after initial management.
During a 21-year experience at our center, 1,352 patients underwent SRS as management for their acoustic neuromas. We retrospectively identified 6 patients who underwent SRS twice for the same tumor. The median patient age was 47 years (range, 35-71 years). All patients had imaging evidence of tumor progression despite initial SRS. One patient also had incomplete surgical resection after initial SRS. All patients were deaf at the time of the second SRS. The median radiosurgery target volume at the time of the initial SRS was 0.5 cc and was 2.1 cc at the time of the second SRS. The median margin dose at the time of the initial SRS was 13 Gy and was 11 Gy at the time of the second SRS. The median interval between initial SRS and repeat SRS was 63 months (range, 25-169 months).
At a median follow-up of 29 months after the second SRS (range, 13-71 months), tumor control or regression was achieved in all 6 patients. No patient developed symptomatic adverse radiation effects or new neurological symptoms after the second SRS.
With this limited experience, we found that repeat SRS for a persistently enlarging acoustic neuroma can be performed safely and effectively.
为了评估重复立体定向放射外科(SRS)治疗听神经瘤的结果,我们评估了在初始治疗后肿瘤进展的患者的肿瘤控制、临床结果和放射性不良反应风险。
在我们中心的 21 年经验中,1352 例患者接受了 SRS 作为听神经瘤的治疗。我们回顾性地确定了 6 例因同一肿瘤接受了 2 次 SRS 的患者。患者的中位年龄为 47 岁(范围,35-71 岁)。所有患者尽管接受了初始 SRS,但均有影像学证据显示肿瘤进展。1 例患者在初始 SRS 后还存在不完全手术切除。所有患者在接受第二次 SRS 时均已失聪。初始 SRS 时的中位放射外科靶体积为 0.5cc,第二次 SRS 时为 2.1cc。初始 SRS 时的中位边缘剂量为 13Gy,第二次 SRS 时为 11Gy。初始 SRS 和重复 SRS 之间的中位间隔时间为 63 个月(范围,25-169 个月)。
在第二次 SRS 后中位随访 29 个月(范围,13-71 个月),6 例患者均达到肿瘤控制或消退。第二次 SRS 后无患者出现症状性放射性不良反应或新的神经症状。
根据这有限的经验,我们发现对持续增大的听神经瘤进行重复 SRS 是安全有效的。